Special Issue "Exosomes as Drug Carriers for Cancer Therapy"
Deadline for manuscript submissions: closed (20 August 2023) | Viewed by 4037
Interests: characterization of extracellular vesicles as theranostics; cardiotoxicity from cancer treatment; cardiac repair; paracrine communication; human perinatal stem cells
Special Issues, Collections and Topics in MDPI journals
Interests: clinical application of liquid biopsy; exosome isolation methods; quantitative measurement of exosomes; nucleic acid measurements from exosomes; nucleic acid (gDNA, mtDNA, miRNA and lncRNA) and cell-free nucleic acid isolation; gene expression measurement; comparison of nucleic acid isolation methods; studies in oncological and cardiovascular diseases
Liquid biopsy has several advantages over conventional methods, as it is less invasive, easily obtainable, repeatable, less burdensome for the patient, and more applicable in the diagnosis of distinct diseases (such as oncological, neurological, cardiovascular, and infectious diseases). Early detection, characterization, and monitoring of cancer are possible by using extracellular vesicles (EVs), i.e., mainly exosomes isolated from liquid biopsy samples. Exosomes are packed with several molecules, such as nucleic acids, proteins, lipids, and metabolites. When these are released, they may affect the cell-to-cell communication, contributing to tumorigenesis, angiogenesis, metastasis, signal transduction, and immune responses. We may gather worthwhile information from exosomes to understand their role in the progression of cancer. Several beneficial properties of exosomes make them promising therapeutic shuttle vesicles. Currently, the number of research works focusing on designed drugs or nucleic acids packed into exosomes has skyrocketed. Engineered exosome-based personalized medicine may be a new treatment option for cancer.
This Special Issue aims to address the latest research or new views on exosomes in the monitoring, characterization, and understanding of background mechanisms within cancer, as well as possible therapeutic applications for cancer therapy.
Prof. Dr. Sveva Bollini
Dr. Beáta Soltész
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- extracellular vesicles
- liquid biopsy